Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Megan Webb

Physician Assistant Brookline, MA Physician Assistant

NPI 1679607774 CMS profile 10422025

1101 Beacon St, Brookline, MA 02446

Open in the dashboard

General payments

$14,502

629 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Megan Webb of Brookline, MA is reported in the CMS Open Payments database as having received $14,502 across 629 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,211 144
2024 General $3,189 134
2023 General $3,093 116
2022 General $2,641 122
2021 General $2,368 113

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Megan Webb
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Megan Webb were reported at $3,211. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Megan Webb Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,368 $132 $37–$438 $132
2022 $2,641 $155 $48–$522 $149
2023 $3,093 $167 $52–$557 $160
2024 $3,189 $178 $55–$600 $164
2025 $3,211 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,381 130 payments
  2. Amgen Inc. $1,551 64 payments
  3. Incyte Corporation $1,170 48 payments
  4. Janssen Biotech, Inc. $1,018 38 payments
  5. Novartis Pharmaceuticals Corporation $919 49 payments
  6. Lilly USA, LLC $858 42 payments
  7. UCB, Inc. $784 38 payments
  8. Regeneron Healthcare Solutions, Inc. $651 23 payments
  9. Pfizer Inc. $513 21 payments
  10. E.R. Squibb & Sons, L.L.C. $511 25 payments
  11. Other $3,146 151 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,122 624 payments
  2. Education $380 5 payments
Products named General payments · program years 2021–2025
  1. Otezla $1,551 64 payments
  2. RINVOQ $1,478 50 payments
  3. SKYRIZI $1,331 55 payments
  4. OPZELURA $1,070 47 payments
  5. TREMFYA $739 22 payments
  6. TALTZ $637 29 payments
  7. SOTYKTU $493 24 payments
  8. COSENTYX $490 32 payments
  9. DUPIXENT $457 16 payments
  10. EUCRISA $455 19 payments
  11. Other $7,019 345 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

892

Median for Physician Assistant: 241

Drug cost

$392,742

Median for Physician Assistant: $4,110

Branded share of claims

21.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 18 $156,861
Otezla Apremilast Brand 20 $107,354
Dupixent Pen Dupilumab Brand 22 $99,372
Eucrisa Crisaborole Brand 11 $8,690
Fluorouracil Generic 33 $2,143
Ketoconazole Generic 139 $2,046
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 76 $1,918
Metronidazole Generic 56 $1,832
Betamethasone Valerate Generic 54 $1,430
Clobetasol Propionate Generic 24 $1,190

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$185,450

Of which drugs: $34

Medicare patients

660

Average age 75

Services billed

5,445

405 women, 255 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 58%
Arthritis 38%
Osteoporosis 25%
Cancer 19%
Depression 18%
Ischemic heart disease 15%
Chronic kidney disease 14%
Diabetes 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 22 47 $34

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $499
$499 — —
Otezla
  • Amgen Inc. $453
$453 20 —
SKYRIZI
  • AbbVie, Inc. $386
$386 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $295
$295 — —
OPZELURA
  • Incyte Corporation $204
$204 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

629 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record